Login to Your Account

Galapagos, Merck in Potential €170M Obesity, Diabetes Deal

By Staff Reports

Monday, January 12, 2009

No Abstract

Mechelen, Belgium-based Galapagos NV signed its fifth major pharmaceutical alliance, inking a potential €171.5 million (US$230.4 million)-plus deal with Merck & Co. Inc. to develop drugs aimed at the obesity and diabetes markets.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription